An observational study in Metastatic Colorectal Cancer and Quality of Life, sponsored by Centre Hospitalier Universitaire de Besancon. Status unknown at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-07-22.
Sponsored by Centre Hospitalier Universitaire de Besancon · Observational
The primary aim of this french multicenter national study is to assess and compare time to quality of life score deterioration (targeted dimensions : global health, fatigue and emotional functionning of EORTC QLQC30 according to the first line chemotherapy associated with bevacizumab in metastatic colorectal patients.
5,599 studies on the registry are indexed under Colorectal Neoplasms; 1,459 are open to participants now.
This study's planned enrollment of 320 is above the median of 250 across 1,226 observational studies indexed under Colorectal Neoplasms.
Browse Colorectal Neoplasms studies →Centre Hospitalier Universitaire de Besancon is the lead sponsor of 439 studies on the registry; 97 are open to participants now.
Counted across the registry records on this site, refreshed daily.
metastatic colorectal cancer
Exclusion Criteria:
patients having a 1st line doublet chemotherapy including irinotecan
Drug: Bevacizumab
patients having a 1st line doublet chemotherapy including oxaliplatin
Drug: Bevacizumab
patient having a 1st line triplet chemotherapy including oxaliplatin / irinotecan this cohort was added while primary objective was to compare doublet chemotherapy
Drug: Bevacizumab
time to health related quality of life score deterioration (targeted dimensions of EORTC QLQC30 : global health, fatigue, emotional functioning)
The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients.
Time frame: 1 year
time to health related quality of life score deterioration (non targeted dimensions of EORTC QLQC30 and CR 29)
Time frame: 1 year
INT PATSAT32
The EORTC IN-PATSAT32 is a 32-item satisfaction with care questionnaire to measure patients' appraisal of hospital doctors and nurses, as well as aspects of care organisation and services. It addresses technical competence, information provision, interpersonal skills, availability, waiting time, access, comfort and overall care perception
Time frame: 1 year
quality-adjusted life years (QALYs) using EQ5D
Time frame: 1 year
Overall survival
Time frame: 2 years
Progression Free Survival
Time frame: 1 year
treatment preference
Time frame: 1 year
This study is status unknown, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Universitaire de Besancon